Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis
The Journal of Infectious Diseases · 20.02.2025 · 231 (2) · 532-539
DOI: 10.1093/infdis/jiae409 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, online erschienen am 19.08.2024. Verfasst von Inderpaul Singh Sehgal und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Pulmonary Aspergillosis, Antifungal Agents. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background
The role of 2-deoxy-2-18(F) fluoro-D-glucose (FDG) positron emission tomography (PET)-computed tomography (CT) in assessing treatment response in chronic pulmonary aspergillosis (CPA) remains to be determined. The study objective was to compare FDG-PET/CT parameters in persons with CPA achieving treatment success or failure after 6 months of oral itraconazole.
Methods
We performed PET-CT at baseline and after 6 months of oral itraconazole therapy. FDG uptake similar to the background uptake or ≥13 units decline in Z-score was considered a complete metabolic response (CMR). A >25%, >30%, and > 45% decline in standardised uptake value (SUVmax), SUVpeak, and total glycolytic activity (TLG) was labelled as a partial metabolic response (PMR). A >30%, >30%, or >75% increase in the SUVmax, SUVpeak, and TLG represented progressive metabolic disease.
Results
We included 94 persons with CPA (63 male) with a mean age of 46.2 years. A follow-up PET-CT was performed on 77 participants. We recorded treatment success and failure in 43 and 34 patients. CMR was seen in 18.6% of those with treatment success and none with treatment failure. A higher proportion of patients with treatment success achieved PMR; 19% of the patients with treatment success had progressive metabolic disease.
Conclusions
Most PET-CT parameters improved with treatment; however, PET-CT misclassified one-fifth of the participants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Nuclear Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Radiodiagnosis, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
- Doodhadhari Burfani Hospital, Haridwar, India.
ORCID-Profile: Inderpaul Singh Sehgal, Valliappan Muthu, Arunaloke Chakrabarti
Zitieren
APA
Sehgal, I. S., Arora, K., Agarwal, R., Kumar, R., Rana, N., Dhooria, S., Muthu, V., Prasad, K. T., Garg, M., Rudramurthy, S. M., Aggarwal, A. N., & Chakrabarti, A. (2025). Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis. The Journal of Infectious Diseases, 231(2), 532-539. https://doi.org/10.1093/infdis/jiae409
Vancouver
Sehgal IS, Arora K, Agarwal R, Kumar R, Rana N, Dhooria S, et al. Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis. The Journal of Infectious Diseases. 2025;231(2):532-539. doi:10.1093/infdis/jiae409
BibTeX
@article{Sehgal2025,
author = {Sehgal, Inderpaul Singh and Arora, Kajal and Agarwal, Ritesh and Kumar, Rajender and Rana, Nivedita and Dhooria, Sahajal and Muthu, Valliappan and Prasad, Kuruswamy Thurai and Garg, Mandeep and Rudramurthy, Shivaprakash M and Aggarwal, Ashutosh Nath and Chakrabarti, Arunaloke},
title = {Serial Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography (18FDG-PET-CT) in Assessing Treatment Response in Chronic Pulmonary Aspergillosis},
journal = {The Journal of Infectious Diseases},
year = {2025},
volume = {231},
number = {2},
pages = {532--539},
doi = {10.1093/infdis/jiae409}
}
EUVIMED